PEARCE IP
Our Capabilities
Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.
We coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.
Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.
IP SPECIALISTS LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS
Our Leaders
Naomi Pearce
CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)
Adele Chadwick
Executive, Deputy CEO & Head of Talent
Paul Johns
Executive, Lawyer (Head of Litigation - New Zealand)
Chris Vindurampulle PhD
Executive, Patent & Trade Mark Attorney (Head of Patent Prosecution)
Kimberley Evans
Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks)
Chris Coates (Maj Ret)
Executive, Finance
Helen Macpherson
Executive, Lawyer (Head of Litigation - Australia)
PEARCE IP BLOG
Read our latest updates & insights
![Pearce IP BioBlast® for w/e 19 July 2024](https://www.pearceip.law/wp-content/uploads/2024/07/LINKEDIN-FIRM-NEWS-POST-36-1080x627.png.webp)
Pearce IP BioBlast® for w/e 19 July 2024
19 July 2024 | EU | Gedeon Richter’s EU Denosumab Biosimilars AcceptedOn 19 July 2024, Gedeon Richter announced that...
![How to Handle Roadblocks with an Australian Patent Examiner](https://www.pearceip.law/wp-content/uploads/2024/07/Pearce-IP-Blog-How-to-Handle-Roadblocks-with-an-Australian-Patent-Examiner-1080x627.png.webp)
How to Handle Roadblocks with an Australian Patent Examiner
How to Handle Roadblocks with an Australian Patent Examiner
Apple Inc. [2024] APO 25 (25 June 2024)
Amazentis SA [2024] APO 27 (28 June 2024)
![Pearce IP BioBlast® for w/e 19 July 2024](https://www.pearceip.law/wp-content/uploads/2024/07/LINKEDIN-FIRM-NEWS-POST-36-1080x627.png.webp)
Pearce IP BioBlast for w/e 12 July 2024
12 July 2024 | HK | IS | Approval Alert: Eisai’s Leqembi® (Lecanemab) Approved in Hong Kong and Israel for Alzheimer's...
Product specific reports based on extracts from our BioBlast® database
adalimumab | Humira® | AbbVie
aflibercept | Eylea® | Regeneron
bevacizumab | Avastin® | Roche/Genentech
cetuximab | Erbitux® | BMS/Merck
darbepoetin | Aranesp® | Amgen
denosumab | Prolia®/Xgeva® | Amgen
dupilumab | Dupixent® | Sanofi-Aventis
eculizumab | Soliris® | Alexion
filgrastim (GCSF) | Neupogen® | Amgen
golimumab | Simponi® | Janssen
guselkumab | Tremfya® | Janssen
infliximab | Remicade® | Johnson & Johnson
ixekizumab | Taltz® | Eli Lilly
natalizumab | Tysabri® | Biogen/Elan
omalizumab | Xolair® | Genentech / Novartis
pegfilgrastim | Neulasta® | Amgen
pembrolizumab | Keytruda® | Merck
pertuzumab | Perjeta® | Roche
ranibizumab | Lucentis® | Genentech
regdanvimab | Regkirona® | Celltrion
risankizumab | Skyrizi® | AbbVie
rituximab | Rituxan®/MabThera® | Genentech/Biogen
secukinumab | Cosentyx® | Novartis
tocilizumab | Actemra® | Roche
trastuzumab | Herceptin® | Roche/Genentech
OUR VISION
By 2027, be the premier life sciences IP practice in
Australia and New Zealand.
AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS
Awards
![](https://www.pearceip.law/wp-content/uploads/2024/06/Australasian-Lawyer-2.png.webp)
Australasian Lawyer
![](https://www.pearceip.law/wp-content/uploads/2024/06/MIP_IP_Stars_logo_draft_final_bold_star.png)
MIP Stars
![](https://www.pearceip.law/wp-content/uploads/2024/06/iam2-mobile-logo.png.webp)
IAM Patent 1000 2024
![](https://www.pearceip.law/wp-content/uploads/2023/10/Lexology-Legal-Influencers_Email-Sig_Q3-2023.png.webp)
Lexology Q3 2023
![](https://www.pearceip.law/wp-content/uploads/2024/07/Legal-500-leading-firm-2024-30.png)
Legal 500 2024
![](https://www.pearceip.law/wp-content/uploads/2023/07/award-banner-2.jpg.webp)
![](https://www.pearceip.law/wp-content/uploads/2022/06/WIPR-badge-slider.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2022/07/Q2-2022-Lexology-Legal-Influencers-banner.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-iam-1000.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2022/07/banner-ALA_2022_Intellectual-Property-Team-of-the-Year-1.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/12/Logo-women-law.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/12/Logo-australian-law-awards.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-lexology-q2-2021.png.webp)
Lexology Q2 2021
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-doyles-2021.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-iam-300.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-doyles-2020.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2023/01/Legal-500-Award-Seal-for-scroll.jpg)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-wipr-leaders-2021.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-wipr-diversity.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-wipr-ip.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2021/09/Logo-lexology-q1-2021.png.webp)
![](https://www.pearceip.law/wp-content/uploads/2023/01/Legal-Infuecner-Q4-Award-Seal.jpg)
![](https://www.pearceip.law/wp-content/uploads/2023/01/Clients-Choice-Trailing-line-of-awards.jpg)